c-di-AMP |
|
Vaxjo ID |
398 |
|
Vaccine Adjuvant Name |
c-di-AMP |
|
Alternative Names |
c-di-AMP is also known as cyclic di-adenosine monophosphate. |
|
Adjuvant VO ID |
VO_0005680
|
|
Description |
c-di-AMP is a bacterial second messenger that exhibits strong immune-modulatory properties, stimulating both humoral and cellular immune responses. |
|
Stage of Development |
Research |
|
Host Species for Testing |
3 |
|
Components |
bis-(3',5')-cyclic dimeric adenosine monophosphate (c-di-AMP) |
|
Structure |
c-di-AMP consists of two adenosine monophosphate (AMP) molecules linked by two phosphate groups in a cyclic arrangement. |
|
Preparation |
c-di-AMP was obtained from a supplier (Biolog, Germany) and was used in the study in specified concentrations. |
|
Dosage |
In the study, c-di-AMP was administered at a concentration of 5 ug per dose. |
|
Function |
We have shown previously that bis-(3',5')-cyclic dimeric adenosine monophosphate (c-di-AMP) constitutes a promising adjuvant candidate stimulating both effective Th1/Th2 and cytotoxic immune responses when included in mucosal or parenteral vaccine formulations. In the present work we demonstrate that c-di-AMP can be also combined with other adjuvants like alum resulting in increases in not only humoral responses but more striking also in cellular immune responses. This leads to improved vaccine efficacy against intracellular pathogens. It activates NLRP3 inflammasome and forms a depot for slow antigen release. |
|
Safety |
The article indicates that c-di-AMP has promising safety profiles as it is derived from bacterial sources and has been shown not to induce unwanted side effects in the studied models. |
| References |
Ebensen et al., 2019: Ebensen T, Delandre S, Prochnow B, Guzmán CA, Schulze K. The Combination Vaccine Adjuvant System Alum/c-di-AMP Results in Quantitative and Qualitative Enhanced Immune Responses Post Immunization. Frontiers in cellular and infection microbiology. 2019; 9; 31. [PubMed: 30838180].
|
